Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
THEO-310
- Development stage
- Preclinical
- Lead developer
- Theolytics
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intravenous
01
Overview
THEO-310 is a novel oncolytic adenovirus developed by Theolytics for the treatment of multiple myeloma. It is designed to target the bone marrow tumor microenvironment (TME) of advanced, late-stage myeloma patients. THEO-310 features a rare viral capsid composition that allows it to bypass recognition by neutralizing antiviral antibodies, enabling effective systemic intravenous delivery. The virus selectively infects and replicates within malignant cells, leading to direct cell lysis. Additionally, THEO-310 alleviates immune suppression in the TME and stimulates anti-tumor immune responses, including the upregulation of natural killer (NK) cell degranulation markers and effector T-cell and dendritic cell responses.
Beyond the preview
Go deeper on THEO-310.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on THEO-310.